Trial Profile
A Prospective Observational Study to Evaluate Quality of Life and Costs in a Real Life Setting in Patients Treated With 90Y-Zevalin.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Sep 2010
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions
- Sponsors Bayer
- 28 Jul 2010 New trial record